Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03125616
Other study ID # 16.0247
Secondary ID 2017-001487-38
Status Completed
Phase Phase 4
First received
Last updated
Start date August 1, 2017
Est. completion date August 28, 2020

Study information

Verified date November 2020
Source St George's, University of London
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In the UK, babies receive their vaccinations according to a standard schedule, irrespective of their gestation at birth. This policy is designed so that all babies are protected as early as possible from vaccine preventable diseases such as polio, diphtheria, tetanus, rotavirus, pertussis (whooping cough), Haemophilus influenzae type B, pneumococcal disease and now meningococcal B disease. The 4CMenB vaccination (Bexsero®) was added to the UK schedule in September 2015 and there has been no research looking at whether the vaccine gives the same protection to babies born early as it does to those born at term. The Investigators want to compare two different schedules of 4CMenB and see if one gives better protection to babies born prematurely. It is possible that an extra 4CMenB dose (i.e. three doses in early infancy instead of two) will offer better protection for premature babies. This is what the Investigators are trying to find out through this study.


Description:

This will be an open label, phase IV study. After appropriate consent, 132 premature infants born at <35 weeks gestation (i.e. up to 34 weeks and 6 days), 50% <30 weeks gestation (i.e. up to 29 weeks and 6 days) will be randomised to 1 of 2 4CMen B schedules either at 2,4 and 12 months or 2,3,4 and 12 months. Babies will remain in the study for around 12 months, from recruitment to 13 months of age. All visits can be performed at the participant's home or in clinic, depending on the preference of the parents and study team. Blood samples will be obtained at 5 months of age (post primary sample), 12 months (persistence sample) and 13 months (post booster sample). Reactogenicity and safety will be assessed by caregiver completion of a 7-day diary after each vaccine dose. Inpatients will be monitored for cardiorespiratory events for 72 hours after vaccination by healthcare staff and this information will be collected on the CRF. This will include details of oxygen saturations, heart rate, respiratory rate and details of any episodes of desaturation, bradycardia or apnoea. Particular emphasis will be placed on rates, timing and intensity of fever and other adverse reactions in the first 24 hours after vaccination, because this remains a cause of great concern amongst neonatologists.


Recruitment information / eligibility

Status Completed
Enrollment 136
Est. completion date August 28, 2020
Est. primary completion date September 2, 2019
Accepts healthy volunteers No
Gender All
Age group 7 Weeks to 11 Weeks
Eligibility Inclusion Criteria: - Premature infant born at <35 weeks gestation - No contraindications to vaccination according to the 'Green Book' - Willing and able to comply with study procedures - Written informed consent Exclusion Criteria: - Contraindication to vaccination according to the Green Book - Life-limiting congenital abnormality or condition - Prior diagnosis of an immunodeficiency syndrome - Considered unlikely to complete expected follow up until the end of the study

Study Design


Intervention

Biological:
4CMenB Vaccine
The infants will receive an intramuscular injection of the 4CMenB vaccine at 2 months
4CMenB Vaccine
The infants will receive an intramuscular injection of the 4CMenB vaccine at 3 months
4CMenB Vaccine
The infants will receive an intramuscular injection of the 4CMenB vaccine at 4 months
4CMenB Vaccine
The infants will receive an intramuscular injection of the 4CMenB vaccine at 12 months

Locations

Country Name City State
United Kingdom St Georges University Hospital NHS Foundation Trust Tooting London

Sponsors (4)

Lead Sponsor Collaborator
St George's, University of London GlaxoSmithKline, MeningitisNow, Public Health England

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary hSBA GMT hSBA GMT one month after completing primary immunisations for relevant 4CMenB (Bexsero®) antigens: fHbp, NadA and PorA Tested in each infant at 5 months of age (1 month after completion of primary vaccinations)
Primary hSBA proportions hSBA proportions = 1:4, one month after completing primary immunisations for relevant 4CMenB (Bexsero®) antigens: fHbp, NadA and PorA. Tested in each infant at 5 months of age (1 month after completion of primary vaccinations)
Secondary Reactions within 7 days The percentage of infants experiencing fever, local reactions and non-febrile systemic reactions within the 7 days following each vaccine dose Assessed in each infant for the 7 days following vaccination
Secondary Cardiorespiratory status for 72 hours following vaccination The percentage of inpatients experiencing change / deterioration in cardiorespiratory status within the 72 hours following each vaccine dose Assessed in all infants in hospital for 72 hours following vaccination
Secondary Suspicion of sepsis in 7 days following vaccination The percentage of infants investigated for sepsis and commenced on antibiotics within 7 days of vaccination Assessed in all infants in the 7 days following vaccination
Secondary Fever and/or suspicion of sepsis in the 28 days following vaccination The percentage of infants who experience fever and/or are investigated for sepsis and commenced on antibiotics within 28 days of vaccination Assessed in all infants in the 28 days following vaccination
Secondary Serious adverse events The percentage of infants who experience a serious adverse event at any point within the study Assessed in all infants at the conclusion of the study
Secondary Persistence of hSBA GMTs hSBA GMTs at 12 months of age (pre booster) for relevant 4CMenB (Bexsero®) antigens: fHbp, NadA and PorA Assessed in all infants at 12 months of age
Secondary Persistence of hSBA proportions =1:4 hSBA proportions =1:4, at 12 months of age (pre booster) for relevant 4CMenB (Bexsero®) antigens: fHbp, NadA and PorA Assessed in all infants at 12 months of age
Secondary Booster response: hSBA GMTs hSBA GMTs at 13 months of age (post booster) for relevant 4CMenB (Bexsero®) antigens: fHbp, NadA and PorA; Assessed in all infants at 13 months of age
Secondary Booster response: hSBA proportions =1:4 hSBA proportions =1:4, at 13 months of age (post booster) for relevant 4CMenB (Bexsero®) antigens: fHbp, NadA and PorA. Assessed in all infants at 13 months of age
See also
  Status Clinical Trial Phase
Recruiting NCT03670732 - CPAP vs.Unsynchronized NIPPV at Equal Mean Airway Pressure N/A
Completed NCT05322161 - Yoga in the NICU for Parents Study N/A
Recruiting NCT04542096 - Real Time Evaluation of Dynamic Changes of the Lungs During Respiratory Support of VLBW Neonates Using EIT
Recruiting NCT04911452 - Creating a Calmer NICU: Optimizing Growth and Brain Development in Preterm Infants N/A
Recruiting NCT02901652 - NIPPV and nBiPAP Methods in Preterm Infants With Respiratory Distress Syndrome N/A
Completed NCT02148965 - Effects of Exercise During Pregnancy on Maternal and Child Health: a Randomized Clinical Trial N/A
Completed NCT02273843 - A Trial on Different Dosages of Vitamin D in Preterm Infants With Late-onset Sepsis Phase 1
Terminated NCT02032511 - Comparison of RAM Cannula Nasal Continuous Positive Airway Pressure Versus Infant Flow Nasal Continuous Positive Airway Pressure (NCPAP) N/A
Completed NCT01721629 - Weaning of Nasal Continuous Positive Airway Pressure (CPAP) in Premature Infants N/A
Terminated NCT01819532 - Milking the Umbilical Cord Versus Immediate Clamping in Pre-term Infants < 33 Weeks N/A
Completed NCT00951860 - Assessment of Autonomic Maturation in Neonatal Period and Early Neural Development From a Longitudinal Prospective Cohort N/A
Completed NCT01478711 - Comprehensive Clinical Decision Support (CDS) for the Primary Care of Premature Infants N/A
Completed NCT01523769 - Umbilical Cord Milking on the Reduction of Red Blood Cell Transfusion Rates in Infants N/A
Completed NCT00787124 - Transfusions and Nitric Oxide Level in Preterm Infants
Completed NCT00749008 - Study of Generalized Movements for Early Prediction of Cerebral Palsy N/A
Terminated NCT00486395 - Will CPAP Reduce Length Of Respiratory Support In Premature Infants? Phase 3
Completed NCT00527956 - Facilitation and Barriers to Breastfeeding in the NICU N/A
Terminated NCT01208493 - Dietary Protein in the Very-low-birth-weight Infant N/A
Completed NCT03372590 - NEO Rehab for Infants at Risk of Cerebral Palsy N/A
Completed NCT00033917 - Indomethacin Germinal Matrix Hemorrhage/Intraventricular Hemorrhage (GMH/IVH) Prevention Trial Phase 3